J. Spona

No ORCID on file · 7 papers in corpus · active 1977-1999

Study types

  • article 6
  • book-chapter 1

Condition tags

  • endometriosis 1
article 1999
Clinical profile of Valette®
·doi:10.3109/13625189909085261

Studies have been undertaken to investigate the modulatory effects of a combination of 30 μg ethinylestradiol and 2.00 mg dienogest (Valette®) on ovarian function and on the hemostatic system. Modulation of ovarian function was investigated…

article 1998
Dienogest
·doi:10.2165/00003495-199856050-00009
article 1997
Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system
·doi:10.1016/s0010-7824(97)00094-2
article 1997
Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest
·doi:10.1016/s0010-7824(97)00123-6
article 1989
[Long-term follow-up of 14 patients with endometriosis, who were treated with the LHRH analog buserelin].
Gynakologische Rundschau
article 1977
[A new antigonadotropin in the treatment of precocious puberty and pubertal gynaecomastia (author's transl)].

A synthetic steroid compound derived from testosteron (isoxazol-ethisterone), Danazol, with gonadotropin-depressing activity, was used in the treatment of 4 cases of idiopathis sexual precocity (age 2 1/2 to 4 years) and in 10 cases of seve…

book-chapter 1977
Ein neues „Antigonadotropin“ in der Behandlung der Pubertas praecox und der Pubertätsgynäkomastie
·doi:10.1007/978-3-7091-8491-2_12